Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...

The La Jolla, California-based biotech licensed its first drug – itolizumab for graft-versus-host disease (GvHD), asthma and lupus nephritis – from Indian drugmaker Biocon in 2017. The Bioniz ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...

The study, which was co-sponsored with Biocon (NSE:BION) Limited, included a total of 90 biologic-naïve patients who were randomized to receive either itolizumab, a placebo, or adalimumab ...

The data suggests high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added t ...

Equillium’s itolizumab downregulates T effector cell activity and trafficking to tissues. It is currently being tested against acute graft-vs-host disease (aGVHD), lupus nephritis, and ...